Stock NUVB NUVATION BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Nuvation Bio Inc.

Equities

NUVB

US67080N1019

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 10:23:47 2024-04-23 am EDT 		5-day change 1st Jan Change
2.755 USD +2.80% Intraday chart for Nuvation Bio Inc. -1.60% +83.11%
Apr. 17 RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk MT
Apr. 10 Nuvation Bio Closes Acquisition of AnHeart Therapeutics MT

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Number of employees: 51

Managers

Managers TitleAgeSince
David Hung FOU
 Founder 66 18-03-19
Moses Makunje DFI
 Director of Finance/CFO 46 20-06-30
Dong Fang Liu CTO
 Chief Tech/Sci/R&D Officer 54 22-07-17
Gary Hattersley CTO
 Chief Tech/Sci/R&D Officer 57 19-05-31
David Hanley PRN
 Corporate Officer/Principal 54 21-05-31
Stacy Markel HRO
 Human Resources Officer 59 19-09-30
Kerry Wentworth LAW
 General Counsel 51 22-07-17

Members of the board

Members of the board TitleAgeSince
David Hung FOU
 Founder 66 18-03-19
Kim Blickenstaff BRD
 Director/Board Member 71 19-07-31
Kathryn Falberg BRD
 Director/Board Member 63 20-09-30
Daniel Welch CHM
 Chairman 66 20-06-30
Robert D. Mashal BRD
 Director/Board Member - Jan. 07
Tony Vernon BRD
 Director/Board Member 68 19-05-31
Robert B. Bazemore BRD
 Director/Board Member 56 20-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,000,000 0 0 75.17 %
Stock B 1 245,692,474 185,427,238 ( 75.47 %) 0
Stock C 0 851,202 0 0

Shareholders

NameEquities%Valuation
David Hung
26.73 %
58,281,054 26.73 % 212 M $
Fidelity Management & Research Co. LLC
11.98 %
26,130,659 11.98 % 95 M $
EcoR1 Capital, LLC
8.810 %
19,209,643 8.810 % 70 M $
Omega Fund Management LLC
6.912 %
15,072,340 6.912 % 55 M $
Vanguard Fiduciary Trust Co.
3.355 %
7,314,615 3.355 % 27 M $
Decheng Capital LLC
2.831 %
6,172,344 2.831 % 22 M $
Abrams Capital Management LP
1.748 %
3,811,513 1.748 % 14 M $
Tang Capital Management LLC
1.605 %
3,500,000 1.605 % 13 M $
Millennium Management LLC
1.419 %
3,094,669 1.419 % 11 M $
STATE STREET CORPORATION
1.404 %
3,062,214 1.404 % 11 M $
NameEquities%Valuation
David Hung
6.368 %
1,000,000 6.368 % 4 M $
NameEquities%Valuation
BlackRock Advisors LLC
-
12,500,002 - 4 M $
Citadel Securities GP LLC
-
3,051,047 - 924 467 $
EcoR1 Capital, LLC
-
963,333 - 291 890 $
683 Capital Management LLC
-
835,323 - 253 103 $
Barclays Bank Plc
-
488,390 - 147 982 $
BlackRock Investment Management LLC
-
478,550 - 145 001 $
Adage Capital Partners GP LLC
-
266,666 - 80 800 $
Boxer Capital LLC
-
266,666 - 80 800 $
Franklin Advisers, Inc.
-
266,666 - 80 800 $
Deerfield Management Co. LP (Private Equity)
-
166,666 - 50 500 $

Company contact information

Nuvation Bio, Inc.

1500 Broadway Suite 1401

10036, New York

+

http://www.nuvationbio.com
address Nuvation Bio Inc.(NUVB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.68 USD
Average target price
6.6 USD
Spread / Average Target
+146.27%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NUVATION BIO INC. Stock Nuvation Bio Inc.
+83.11% 704M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.04% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+49.28% 40.08B
MODERNA, INC. Stock Moderna, Inc.
+7.33% 40B
CELLTRION, INC. Stock Celltrion, Inc.
-11.32% 26.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.24% 24.58B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.22% 18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.52% 11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+19.21% 11.66B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+9.03% 11.01B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NUVB Stock
  4. Company Nuvation Bio Inc.